Some of the most pressing issues in modern immunoncology is to identify biomarkers that can predict patients outcomes, not only for the predictive capability but also for personalized predictive capability. How do host genetic factors modulate melanoma immunotherapy outcomes? We asked Tomas Kirchhoff (Department of Population Health Associate Professor, Department of Environmental Medicine, Perlmutter Cancer Center, New York) during Immunotherapy Bridge Congress in Naples.
FONTE: www.oncoinfo.it
